FDA Grants IBsolvMIR Orphan Drug designation in the treatment of diabetes patients in the U.S.

TikoMed AB, a biotechnology company focused on development and commercialization of innovative treatments for immune diseases and cell therapies, today announced that IBsolvMIR® has been granted orphan drug designation for the prevention of graft rejection of pancreatic islet transplantation by the U.S. Food and Drug Administration (FDA). IBsolvMIR is a unique new treatment which could transform islet cell transplantation into a standard treatment for severe type 1 diabetes patients with unstable diabetic conditions. TikoMed's product IBsolvMIR improves the survival of transplanted cells by inhibiting a destructive immunological reaction and through stimulation of growth factors.

The FDA's orphan drug designation is reserved for new therapies being developed to treat diseases or conditions that affect fewer than 200,000 people in the U.S. The orphan drug designation provides for an accelerated review process, tax benefits, exemption from user fees and a seven-year period of market exclusivity in the U.S. after product approval. Hence, IBsolvMIR will not meet any generic competition during this period and can also without user fees receive FDA assistance in the design of clinical trials.

"Receiving U.S. orphan drug designation for IBsolvMIR is extremely gratifying as there is an acute need for more treatment options for patients with severe type 1 diabetes with unstable diabetic conditions," said Adam Bruce, Chairman of TikoMed. "Aside from the opportunity to improve quality of life for these patients, the designation provides free assistance for the execution of clinical studies, so we are making significant progress towards commercialization on the U.S. market."

IBsolvMIR is in development to improve islet cell transplantation for patients with severe type 1 diabetes. An ongoing phase II clinical study has gained a $15 million grant from the National Institutes of Health (NIH) through Uppsala University, Sweden. IBsolvMIR has the ability to improve the transplantation outcome through avoiding destruction of the insulin producing islet cells by the immune system. Successful islet transplantation has the potential to make severe type 1 diabetics insulin independent and avoid hypoglycemic crises. In a previous phase I study, IBsolvMIR was well tolerated by healthy volunteers, with no dose-limiting adverse effects documented.

"The orphan drug designation strengthens TikoMed's competitive position as exclusive marketing rights in the U.S. are very valuable," said Anders Waas, CEO of TikoMed. "This is a complement to our patent portfolio, adding value in our discussions for collaborations to develop and commercialize IBsolvMIR in the U.S."

About TikoMed
Swedish-based TikoMed is an innovation driven biotechnology company focused on the development and commercialization of novel treatments for cell transplantation and immune diseases. Currently, TikoMed has three products in development:

  • IBsolvMIR, which in addition to islet cell transplantation also has the potential to improve the outcome of other transplantations, such as liver and bone marrow transplantations.
  • TM-110, is an oral product which can eliminate IP-10, a pro-inflammatory chemokine. It provides an opportunity for safe and effective treatment of severe autoimmune diseases, where there is a high unmet need. Ongoing studies are documenting the product utility for inflammatory bowel disease (ulcerative colitis and Crohn's disease), a $3 billion market.
  • TM-120, is an apheresis product for autoimmune and inflammatory diseases. It binds and down regulates IP-10, a pro-inflammatory chemokine. It will first be developed for rheumatoid arthritis. The market for treatment of rheumatism is larger than $8 billion and there is a significant unmet need for improved treatments.

For more information, please visit www.tikomed.com.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...